Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $34

Benzinga · 3d ago
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $16 to $34.